About
One board for the peptide pipeline
Peptide Exchange turns the news about peptide drugs into moves on a single board, so a reader can see in one glance where a molecule stands and what changed it.
Last updated
What we track
The board follows 33 peptide molecules held by 22 companies: incretin and amylin drugs for obesity and diabetes, GLP-2 analogs for the gut, peptide hormones, immune blockers taken as tablets, and peptides for blood and cholesterol. Each one has its own page with its stage history and every story about it.
What a move is
A move is one event that changes, or confirms, where a molecule stands: an approval, a filing, a trial readout, a deal or a setback. Every story carries a signal (up, flat or down), the stage it started from and the stage it reached, the region it happened in and its primary source. The news archive lists all 57 of them, newest first.
Who runs it
The site is run by a small independent team and publishes under its own name, without personal bylines. Drafts are prepared with AI assistance from the documents each story cites and checked before and after they go live; the method page sets out every step, how sources are chosen and how corrections work.
What we leave out
- No advertising, sponsored content, affiliate links or shop listings.
- No doses, no sourcing, no stock tips.
- No personal medical advice; the disclaimer says why.
Questions, corrections and pointers to public documents reach us through the contact form.